Drug Search Results
More Filters [+]

Levomilnacipran

Alternative Names: levomilnacipran, f2695, milnacipran hydrochloride, fetzima
Latest Update: 2024-12-10
Latest Update Note: Clinical Trial Update

Product Description

Levomilnacipran is an antidepressant medication that works in the brain. It is approved for the treatment of major depressive disorder (MDD). (Sourced from: https://www.nami.org/About-Mental-Illness/Treatments/Mental-Health-Medications/Types-of-Medication/Levomilnacipran-(Fetzima))

Mechanisms of Action: Serotonin/Noradrenaline Reuptake Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Brazil | Canada | Chile | Egypt | France | Hong Kong | India | Mexico | Taiwan | Thailand | Turkey | United Kingdom | United States | Vietnam

Approved Indications: Fibromyalgia | Myalgia | Depressive Disorder | Depressive Disorder, Major | Fibromyalgia | Myalgia

Known Adverse Events: Hypertension | Dizziness | Headache | Hyperhidrosis | Constipation | Erectile Dysfunction

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levomilnacipran

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events